Personal information

China

Activities

Employment (1)

Sir Run Run Shaw Hospital: Hangzhou, CN

(Department of Hematology)
Employment
Source: Self-asserted source
Linlin Shi

Education and qualifications (1)

Zhejiang University: Hangzhou, CN

Education
Source: Self-asserted source
Linlin Shi

Professional activities (1)

Sir Run Run Shaw Hospital: Hangzhou, CN

Distinction
Source: Self-asserted source
Linlin Shi

Works (10)

Recent advances in engineering prodrug-based nanomedicines for cancer therapy

Materials Advances
2024 | Journal article
Contributors: Linlin Shi; Shanshan Lin; Fengping Zhou; Hao Jiang; Jin Zhang
Source: check_circle
Crossref

Research advances in nanomedicine applied to the systemic treatment of colorectal cancer

International Journal of Cancer
2023 | Journal article
EID:

2-s2.0-85137439216

Part of ISSN: 10970215 00207136
Contributors: Yin, L.; Li, H.; Shi, L.; Chen, K.; Pan, H.; Han, W.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

An esterase-activatable prodrug formulated liposome strategy: Potentiating the anticancer therapeutic efficacy and drug safety

Nanoscale Advances
2022 | Journal article
EID:

2-s2.0-85124298528

Part of ISSN: 25160230
Contributors: Shi, L.; Wu, X.; Li, T.; Wu, Y.; Song, L.; Zhang, W.; Yin, L.; Wu, Y.; Han, W.; Yang, Y.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

Quantitative self-assembly of photoactivatable small molecular prodrug cocktails for safe and potent cancer chemo-photodynamic therapy

Nano Today
2021 | Journal article
EID:

2-s2.0-85097450790

Part of ISSN: 1878044X 17480132
Contributors: Huang, L.; Wan, J.; Wu, H.; Chen, X.; Bian, Q.; Shi, L.; Jiang, X.; Yuan, A.; Gao, J.; Wang, H.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy

ACS Applied Materials and Interfaces
2020 | Journal article
EID:

2-s2.0-85077468656

Part of ISSN: 19448252 19448244
Contributors: Han, W.; Shi, L.; Xie, B.; Wan, J.; Ren, L.; Wang, Y.; Chen, X.; Wang, H.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts

Journal of Controlled Release
2020 | Journal article
EID:

2-s2.0-85085176804

Part of ISSN: 18734995 01683659
Contributors: Shi, L.; Wang, Y.; Wang, Q.; Jiang, Z.; Ren, L.; Yan, Y.; Liu, Z.; Wan, J.; Huang, L.; Cen, B. et al.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer

Theranostics
2019 | Journal article
EID:

2-s2.0-85074701306

Part of ISSN: 18387640
Contributors: Han, W.; Xie, B.; Li, Y.; Shi, L.; Wan, J.; Chen, X.; Wang, H.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer

Signal Transduction and Targeted Therapy
2018 | Journal article
EID:

2-s2.0-85058559542

Part of ISSN: 20593635 20959907
Contributors: Han, W.; Shi, L.; Ren, L.; Zhou, L.; Li, T.; Qiao, Y.; Wang, H.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations

Theranostics
2017 | Journal article
EID:

2-s2.0-85028566773

Part of ISSN: 18387640
Contributors: Wang, H.; Chen, J.; Xu, C.; Shi, L.; Tayier, M.; Zhou, J.; Zhang, J.; Wu, J.; Ye, Z.; Fang, T. et al.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier

Roles of PFKFB3 in cancer

Signal Transduction and Targeted Therapy
2017 | Journal article
EID:

2-s2.0-85053729087

Part of ISSN: 20593635 20959907
Contributors: Shi, L.; Pan, H.; Liu, Z.; Xie, J.; Han, W.
Source: Self-asserted source
Linlin Shi via Scopus - Elsevier